Managing Rheumatoid Arthritis Flares

Immediate Flare Management

• Glucocorticoids can be administered via different routes (oral, intramuscular, or intra-articular) depending on the distribution of joint involvement, as recommended by the European League Against Rheumatism 1
• Taper glucocorticoids as rapidly as clinically feasible once disease control is achieved, according to the European League Against Rheumatism 1

Optimize Current DMARD Therapy

• For patients already on combination conventional synthetic DMARDs who flare, proceed directly to biologic therapy rather than adjusting conventional DMARDs further, as suggested by the European League Against Rheumatism 1

Treatment Escalation Algorithm

• Alternative first-line biologics include IL-6 inhibitors (tocilizumab, sarilumab), which may be preferred if methotrexate cannot be used as comedication, as recommended by the European League Against Rheumatism 1
• Consider adding combination conventional synthetic DMARDs (triple therapy: methotrexate + sulfasalazine + hydroxychloroquine) before advancing to biologics, according to the American College of Rheumatology and the European League Against Rheumatism 1, 2

Monitoring and Treatment Adjustment

• Reassess disease activity every 1-3 months during active disease using validated composite measures (SDAI, CDAI, or DAS28), as recommended by the European League Against Rheumatism 1
• If no improvement occurs by 3 months, adjust therapy immediately, according to the European League Against Rheumatism 1
• If the treatment target is not reached by 6 months, escalate therapy, as suggested by the European League Against Rheumatism 1

Treatment Targets

• Primary target: Clinical remission (SDAI ≤3.3 or CDAI ≤2.8), as defined by the American College of Rheumatology 3
• Acceptable alternative: Low disease activity (SDAI ≤11 or CDAI ≤10), particularly in patients with long-standing disease, according to the American College of Rheumatology 3

If First Biologic Fails

• Switch to either a different TNF inhibitor (50-70% response rate expected) or a non-TNF biologic with a different mechanism of action, as recommended by the American College of Rheumatology 2
• After failure of one TNF inhibitor, switching to a non-TNF biologic may provide better outcomes than switching to another TNF inhibitor, though either approach is acceptable, according to the American College of Rheumatology 2

Critical Pitfalls to Avoid

• Do not continue ineffective therapy beyond 3 months hoping for delayed response—this allows irreversible joint damage to progress, as warned by the European League Against Rheumatism 1
• After starting glucocorticoids, do not continue beyond 3 months at doses >10 mg/day due to cumulative toxicity including osteoporosis, cardiovascular disease, and cataracts, as cautioned by the American College of Rheumatology and the European League Against Rheumatism 1, 2

Shared Decision-Making

• All treatment decisions must be made jointly between patient and rheumatologist, incorporating discussion of disease risks, treatment benefits, potential adverse effects, and individual patient factors including comorbidities, as recommended by the European League Against Rheumatism 1, 3

Managing Rheumatoid Arthritis Flares

Immediate Flare Management

• The American College of Rheumatology recommends initiating low-dose glucocorticoids at ≤10 mg/day prednisone (or equivalent) for short-term use (<3 months) to rapidly control inflammation during the flare, with a favorable benefit-risk ratio when dose is low and duration is short 4, 5, 6
• Glucocorticoids should be used to control inflammation during the flare, with the goal of rapidly improving symptoms 4, 5, 6

Assess and Optimize Current DMARD Therapy

• The American College of Rheumatology recommends ensuring methotrexate is optimized to 20-25 mg weekly (oral or subcutaneous) before declaring treatment failure, and escalating therapy if the flare represents inadequate disease control 4, 7
• For patients with moderate/high disease activity (SDAI >11 or CDAI >10) despite optimized DMARD monotherapy, the treatment approach may include adding combination conventional synthetic DMARDs or biologic agents, with the goal of achieving remission or low disease activity 8, 9

Treatment Escalation Algorithm

• For patients with poor prognostic factors, including positive RF or anti-citrullinated protein antibodies, very high disease activity, early joint damage, or failure of 2 conventional synthetic DMARDs, biologic DMARDs may be preferred, with first-line options including TNF inhibitors combined with methotrexate 5, 6, 7
• TNF inhibitors have superior efficacy when combined with methotrexate compared to monotherapy, and alternative first-line biologics include IL-6 inhibitors (tocilizumab, sarilumab) 4, 10

Monitoring and Treatment Adjustment

• The American College of Rheumatology recommends reassessing disease activity every 1-3 months during active disease using validated measures (SDAI, CDAI, or DAS28), and adjusting therapy if no improvement by 3 months or treatment target not reached by 6 months 5, 11, 7
• The treatment target should be remission (SDAI ≤3.3, CDAI ≤2.8) or low disease activity (SDAI ≤11, CDAI ≤10), with the goal of minimizing joint damage and improving quality of life 8, 9, 7

Biologic Therapy

• If first biologic fails, switching to a different TNF inhibitor (50-70% response rate) or a non-TNF biologic with different mechanism (abatacept, rituximab, or tocilizumab) may be considered, with the goal of achieving adequate disease control 8, 5, 10

Steroid Treatment for Rheumatoid Arthritis

Introduction to Steroid Treatment

• The European League Against Rheumatism recommends starting low-dose prednisone (5-10 mg/day) immediately alongside methotrexate to rapidly control inflammation while waiting for DMARD onset of action 12
• Prednisone 7.5-10 mg/day significantly reduces radiographic progression at 12 and 24 months compared to NSAIDs alone, as supported by the American College of Rheumatology 12

Disease-Modifying Effects and Cardiovascular Considerations

• The American Heart Association notes that low-dose glucocorticoids (<10 mg/day) do not significantly contribute to enhanced CV risk and may actually reduce atherosclerosis by suppressing inflammation 13, 14
• High-dose, long-term glucocorticoids clearly increase CV risk through adverse effects on lipids, glucose tolerance, blood pressure, and obesity, according to the European Society of Cardiology 13, 14

Monitoring and Treatment Approach

• The American College of Rheumatology recommends monitoring blood pressure, glucose, and body weight at each visit, as well as bone density assessment at baseline and periodically during treatment 13
• Intra-articular injections of triamcinolone hexacetonide are an effective adjunct for localized joint symptoms, providing short-term relief, as stated by the European League Against Rheumatism 12